Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multi-center, randomized, double-masked, sham-controlled safety and efficacy study of single and repeat intravitreal treatment with Resolv ER™ for the treatment of Vitreomacular Attachment (VMA)

Next Previous
Trial Profile

A multi-center, randomized, double-masked, sham-controlled safety and efficacy study of single and repeat intravitreal treatment with Resolv ER™ for the treatment of Vitreomacular Attachment (VMA)

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 21 Feb 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Resolvine (Primary)
  • Indications Retinal disorders
  • Focus Adverse reactions
  • Sponsors KATO Pharmaceuticals

Most Recent Events

  • 21 Feb 2022 New trial record
  • 16 Feb 2022 According to a KATO Pharmaceuticals media release, the U.S FDA has approved the investigational new drug (IND) application to conduct human studies using Resolv ER™ for the treatment of Vitreomacular Attachment (VMA). Dr. Arshad M.Khanani, MD, MA, will be principal investigator of this study. The company plans to start recruitment in third quarter of 2022.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top